Coprolalia and Tourette Syndrome Without the Stereotypes

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

Coprolalia is a vocal tic that can cause involuntary swearing, obscene words or socially inappropriate language. It can happen in Tourette syndrome, but most people with Tourette syndrome do not have coprolalia. The Centers for Disease Control and Prevention (CDC) states that coprolalia affects about 1 in 10 people with Tourette syndrome, and that people with this tic often feel embarrassed by it.

Coprolalia as a vocal tic

Coprolalia is part of the vocal tic category. Vocal tics are repeated sounds made with the voice, throat, mouth, nose or breathing muscles. They can include sniffing, throat clearing, coughing, grunting, humming, syllables, words or phrases.

The National Institute of Neurological Disorders and Stroke (NINDS) describes complex vocal tics as patterns that may include repeating your own words or phrases, repeating another person’s words or phrases and using vulgar, obscene or swear words.

Coprolalia can sound intentional to people who do not know about tic disorders. The words may be offensive, loud or completely out of context. The person may feel the tic building before it happens and may feel distress afterward. The words should not be treated as a clear statement of the person’s beliefs, values or intent.

Some people can suppress a vocal tic briefly. Suppression can take effort. It may lead to more tension and stronger tics later. This is one reason public judgment can make the experience harder. A person may already be trying hard to hold the tic back.

Why coprolalia is widely misunderstood

Coprolalia is one of the most recognized Tourette symptoms in media, but it is rare compared with other tic symptoms. Most people with Tourette syndrome have motor tics, vocal tics or both without involuntary swearing.

CDC states that media often portray Tourette syndrome as shouting swear words or repeating other people’s words, while these symptoms are rare and are not required for diagnosis.

This public image creates real problems. A child with blinking and throat clearing may not be believed because their symptoms do not match the stereotype. An adult with motor tics and no swearing may be told they do not “look like” they have Tourette syndrome. A person with coprolalia may be judged harshly because others assume the words are deliberate.

Tourette syndrome is diagnosed by tic type, duration, age of onset and clinical pattern. Coprolalia is not required for diagnosis. CDC explains that Tourette syndrome is diagnosed when a person has two or more motor tics and at least one vocal tic, symptoms have lasted at least one year and tics began before age 18.

What coprolalia may sound like

Coprolalia can include swear words, socially taboo words, sexual language, insults or slurs. It may involve one word, a phrase or repeated language. It may occur in a normal speaking voice, a louder tone or a different rhythm than ordinary speech.

The content can be deeply upsetting for the person who has the tic. A child may say something they do not understand. A teen may say something they find humiliating. An adult may fear being seen as aggressive, hateful or unsafe.

Coprolalia can also include mental or whispered words for some people. Not every person with this symptom says the words loudly. Some people experience repeated taboo words internally, which can still be distressing.

The key point for daily support is that the language appears as a tic symptom. It can still hurt others who hear it, so practical planning and respectful response both matter. People around the person can recognize the symptom while also responding to the setting with care.

Public reactions and shame

Public reactions can be one of the hardest parts of coprolalia. People may stare, laugh, confront, record or shame the person. Some may assume the tic is intentional. Others may respond to the word itself without knowing it came from a neurological symptom.

You may feel embarrassed before, during and after a tic. You may avoid public places, school events, work meetings, religious settings, stores, public transport or social gatherings. Avoidance can shrink your daily life and increase anxiety around symptoms.

A short response can help when you choose to explain.

  • “I have Tourette syndrome. That was an involuntary tic.”
  • “That word was a tic. It was not directed at you.”
  • “I understand that sounded upsetting. I have a vocal tic disorder.”
  • “Please do not record me.”

You do not owe strangers a long medical explanation. You can choose when explanation helps and when leaving the setting is safer.

Families, teachers and coworkers can help by staying calm. A shocked reaction can increase attention on the symptom. Mocking, repeating the word or forcing the person to apologize repeatedly can increase shame. A simple, factual response usually works better.

Children and school settings

Coprolalia in school can create major distress because schools have rules about language, respect and classroom behavior. A child may be disciplined for a tic if staff do not know the diagnosis. Other students may laugh, imitate, tease or record the child.

A school plan should clearly explain that coprolalia is a vocal tic. It should also explain how staff should respond. The plan can protect the student while keeping the classroom safe and respectful.

School supports may include the following.

  • Staff education about vocal tics
  • A private response plan for tic episodes
  • Permission to take brief breaks
  • A quiet test setting if vocal tics interfere with testing
  • Anti bullying action
  • A plan for filming or social media issues
  • A trusted staff contact
  • A short explanation for classmates if the student agrees

A child should not be forced to explain the symptom to peers. Some children want classmates to know. Others want privacy. The child’s age, comfort and safety should guide the choice.

Parents can ask the school to avoid punishment for tic symptoms. A student should still be supported in learning respectful social rules, but discipline should account for involuntary symptoms. The response should focus on safety, dignity and education.

Teens and social pressure

Teens with coprolalia may face intense social stress. They may worry about being filmed, mocked or removed from class. They may avoid friendships, sports, events or public places because the language feels too risky.

Teens should have a voice in their support plan. Ask who should know, how teachers should respond, what breaks are acceptable and how peer questions should be handled. A teen may prefer a discreet signal with a teacher or a planned exit option.

Social media risk should be addressed directly. A tic episode can be recorded without consent. Schools should treat filming, posting and mocking as serious behavior. A teen should know which adult to contact if this happens.

Mental health support may be needed if shame, anxiety, depression or avoidance becomes part of daily life. The care plan should look at both the tic and the emotional effect of living with public misunderstanding.

Adults and work settings

Adults with coprolalia may worry about meetings, clients, coworkers, interviews, public roles or shared offices. A vocal tic that includes offensive words can create fear around ordinary work tasks.

Work support should be practical and private when possible. You may choose to disclose only to a manager, human resources contact or trusted coworker. A clinician can help document functional needs if formal accommodations are requested.

Work support may include the following.

  • Brief breaks during tic flares
  • Private space when symptoms intensify
  • Written follow up after meetings
  • Flexible meeting roles
  • Camera or microphone flexibility during virtual calls
  • A short disclosure statement for key coworkers
  • Adjusted duties when public language risk is high

A work plan should protect dignity and safety. It should also recognize that the words may still affect people who hear them. A prepared response can reduce confusion and help others avoid taking the tic as personal intent.

If the tic affects your job, speak with a qualified clinician about treatment options, documentation and related anxiety or stress. You may also need support for ADHD, OCD, mood symptoms or sleep problems if they are present.

Care and support options

Treatment is based on impact. Mild tics may need education and monitoring only. Coprolalia often needs more planning because the social impact can be high, even when the person understands the symptom.

CDC states that behavioral treatment and medication may help when tics cause pain, injury, school issues, work issues, social strain or stress.

Comprehensive Behavioral Intervention for Tics, often called CBIT, may help some people with tic disorders. CBIT teaches tic awareness, competing responses and changes to situations that make tics harder to manage. A trained provider can help decide if CBIT is a fit for the person’s age, tic pattern and daily needs.

Medication may be discussed when tics are severe, disruptive or distressing. Medication decisions require a qualified healthcare professional because benefits, side effects and monitoring needs vary.

Support may also include school accommodations, workplace planning, therapy for anxiety, care for OCD, ADHD treatment and family education. Coprolalia often creates emotional strain, so the plan should address shame, avoidance and public stress along with the tic itself.

How to respond when someone has coprolalia

If someone has a coprolalia tic, respond calmly. Do not laugh, copy the tic, argue with the tic or shame the person. Do not record them. Do not demand a long explanation in public.

A respectful response can be simple.

  • Stay calm
  • Give space if needed
  • Do not repeat the word
  • Do not treat the tic as a personal attack
  • Ask privately what helps
  • Follow the school, work or family plan
  • Step in if others tease, record or harass the person

You can acknowledge that the word may be upsetting while still recognizing the symptom. These two facts can sit together in a practical response. The person with coprolalia may already feel distress about the tic.

For children, adults should lead by example. A teacher, parent or caregiver who responds calmly can shape how peers respond. For adults, a brief explanation at work or in public may reduce confusion.

How coprolalia relates to other vocal tics

Coprolalia is one form of complex vocal tic. Other vocal tics can include humming, throat clearing, sniffing, grunting, coughing, syllables, repeated words or phrases. Echolalia means repeating another person’s words or phrases. Palilalia means repeating your own words or phrases.

A person can have many vocal tics and no coprolalia. A person can also have coprolalia along with motor tics such as blinking, shoulder shrugging, head jerking or facial movements.

The diagnosis depends on the full tic history. Tourette syndrome requires both motor and vocal tics over time. Persistent vocal tic disorder may involve vocal tics without motor tics. Provisional tic disorder may apply when symptoms have lasted less than one year.

If coprolalia appears, it should be discussed with a clinician because it can affect school, work, relationships, safety and mental health.

When to seek clinical help

You should seek clinical help when coprolalia causes school discipline, bullying, work problems, social avoidance, emotional distress, family conflict or public safety concerns. You should also seek help if vocal tics are painful, frequent, severe or linked with other symptoms.

A care visit can review the following.

  • Age when tics began
  • Motor tics and vocal tics
  • When coprolalia began
  • How often it happens
  • Settings where it happens most
  • School, work or public effects
  • Attempts to suppress the tic
  • Anxiety, OCD, ADHD or mood symptoms
  • Sleep and fatigue
  • Medication history
  • Safety concerns

Short videos can help if the person agrees. Tics may not happen during the visit. For children and teens, consent and privacy are important.

Seek urgent support if tics involve self injury, severe depression, suicidal thoughts, threats from others, unsafe situations or sudden neurological changes such as confusion, weakness, fainting or seizure like events.

Common mistakes to avoid

Avoid assuming coprolalia reflects what a person believes. A tic can contain words the person dislikes or fears saying. Treating the tic as intent can increase shame and conflict.

Avoid demanding constant apologies. A brief apology or explanation may be appropriate in some settings, but repeated forced apologies can punish the symptom and make public life harder.

Avoid giving the symptom extra attention. Big reactions can increase pressure around the tic. In schools, staff should correct peer behavior such as teasing, copying and filming rather than making the student’s tic the center of the room.

Avoid telling the person to simply stop. Some people can suppress briefly, but suppression can be draining. It does not remove the tic disorder.

Avoid treating coprolalia as the only sign of Tourette syndrome. Most people with Tourette syndrome do not have coprolalia. Motor tics, vocal tics, tic duration and age of onset are all part of the diagnostic picture.

Links to vocal tics and myths

If you are learning about coprolalia, read a vocal tics guide next. That page should explain throat clearing, humming, sniffing, sounds, words, phrases and other vocal tic patterns.

If you want the wider symptom picture, read a Tourette syndrome symptoms guide. That page should cover motor tics, vocal tics, simple tics, complex tics, premonitory urges and how symptoms change over time.

If you are comparing diagnoses, read a tic disorder guide. That page should explain Tourette syndrome, persistent motor or vocal tic disorder and provisional tic disorder.

If coprolalia is affecting school, work or public life, read a Tourette treatment guide. That page should cover CBIT, medication, care team planning, school support and adult support.

Research context

Coprolalia research sits within the larger study of vocal tics, Tourette syndrome, brain circuits, social response and treatment access. Better research can help clinicians support people whose tics create high public stress.

Regulated psychedelic science is also helping researchers study brain networks, emotion processing and future therapeutic models. Psilocybin is not an established treatment for coprolalia, Tourette syndrome or tic disorders. Any future research in this area should use clear diagnosis, validated tic measures, careful safety review and attention to ADHD, OCD, anxiety and mood symptoms.

Research note

As you review coprolalia, vocal tics and future research questions, we at Rose Hill Life Sciences approach this topic through science led education. Our work focuses on psychedelic research, production and study of Psilocybe cubensis, the intersection of science and therapeutic integration and our Massachusetts research work, while coprolalia diagnosis and treatment decisions should remain with qualified healthcare professionals.

Conclusion

If you or your child has coprolalia, start by documenting the symptom pattern calmly. Note when it began, how often it happens, what settings are hardest and how it affects school, work, social life or emotional health.

Ask a qualified healthcare professional about tic disorder evaluation, CBIT, medication options, care for related conditions and documentation for school or work support.

If you are supporting someone with coprolalia, respond with respect. Do not copy, record or shame the tic. Help the person get practical support and protect their dignity in public settings.

Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.